Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 07 February 2016

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Safety and efficacy of different lanreotide doses for polycystic liver disease

This month's issue of the Alimentary Pharmacology & Therapeutics investigates the safety and efficacy of different lanreotide doses in the treatment of polycystic liver disease.

News image

Long-acting lanreotide 120 mg every 4 weeks reduces liver volume in patients with polycystic liver diseases.

Animal studies that demonstrated that the inhibition of hepatic and renal cystogenesis is dose dependent.

Dr Temmerman and colleagues from Belgium investigated the safety and efficacy of two different LAN doses in polycystic liver diseases patients.

The 6-month results of the LOCKCYST I trial, its extension study, and the LOCKCYST II trial were pooled.

Long-acting lanreotide at baseline and month 6 was measured by CT-scan and blindly re-analyzed by 2 independent radiologists.

Severe side effects with long-acting lanreotide 120 mg was 16%
Alimentary Pharmacology & Therapeutics

The study population consisted of 3 groups.

Each received treatment every 4 weeks during 6 months plus placebo, or long-acting lanreotide at 90 mg or 120 mg.

The team reported excellent inter-observer variability and agreement in the calculation of Long-acting lanreotide.

The researchers observed that severe side effects with placebo, long-acting lanreotide 90 mg and 120 mg were 0%, 7% and 16%, respectively.

Change in long-acting lanreotide after 6 months in these 3 groups included an increase of +36 mL, decrease of −82 mL, and decrease of -123 mL, respecitvely.

Based on ROC analysis, a reduction of 120 mL or more in liver volume has a positive predictive value of 64% for improving symptoms.

Dr Temmerman's team concludes, "Both long-acting lanreotide 90 mg and long-acting lanreotide120 mg reduce liver volume."

"Long-acting lanreotide 90 mg has less side effects. "

"This suggests that in case of intolerance to long-acting lanreotide 120 mg, a dose reduction to long-acting lanreotide 90 mg is meaningful."

Aliment Pharmacol Ther 2013: 38(4): 397–406
06 August 2013

Go to top of page Email this page Email this page to a colleague

 05 February 2016 
Methotrexate and remission in ulcerative colitis
 05 February 2016 
Helicobacter cinaedi bacteremia
 05 February 2016 
Treatment for ileal pouch-anal anastomosis for Crohn’s colitis
 04 February 2016 
Diabetes and liver cancer
 04 February 2016 
Colorectal cancer screening
 04 February 2016 
H. pylori and coronary heart disease 
 03 February 2016 
Acute diverticulitis and IBS 
 03 February 2016 
Microbiota of the colonic mucosa and chronic constipation
 03 February 2016 
Guidelines for chronic pancreatitis
 02 February 2016 
Ramosetron and IBS-diarrhea
 02 February 2016 
IBD emergency department visits
 02 February 2016 
Probiotics for H. pylori management
 01 February 2016 
Managing HBV in pregnancy
 01 February 2016 
Depressive symptoms in IBD 
 01 February 2016 
Obesity and hepatocellular carcinoma risk
 29 January 2016 
Colorectal cancer after colonoscopy
 29 January 2016 
Acute diverticulitis in immunosuppressed patients
 29 January 2016 
Vitamin D and colorectal cancer risk
 28 January 2016 
Tissue anti-TNF drug levels and IBD
 28 January 2016 
First line treatment of H. pylori infection
 28 January 2016 
Tetracycline for rosacea increases the risk of IBD
 27 January 2016 
Steroids in children with Crohn's
 27 January 2016 
Self-management IBS program 
 27 January 2016 
Human gut microbiome in IBD 
 26 January 2016 
Smoking and symptomatic diverticular disease
 26 January 2016 
Step-down therapy in PPI-responsive esophageal eosinophilia 
 26 January 2016 
Diet and IBD risk
 25 January 2016 
IBD monitoring using smartphones
 25 January 2016 
Self-management IBS program
 25 January 2016 
Colorectal cancer after a negative screening sigmoidoscopy
 22 January 2016 
Length of Barrett's and cancer
 22 January 2016 
Psychosocial interventions and alcohol abstinence in chronic liver disease
 22 January 2016 
Helicobacter pylori antibiotic resistance
 21 January 2016 
Increasing adenoma detection rate during colonoscope withdrawal
 21 January 2016 
Microscopic colitis current concepts
 21 January 2016 
Statins as a management strategy for constipation 
 20 January 2016 
Health status after bariatric surgery
 20 January 2016 
Hep E infection in West Africa
 20 January 2016 
Preventing endoscopic bacterial transmission
 19 January 2016 
PPIs and phlebotomy in hereditary hemochromatosis
 19 January 2016 
Predicting liver cirrhosis in Hep C
 19 January 2016 
Frozen vs fresh fecal microbiota transplantation
 18 January 2016 
Hospitalization for diverticulitis in the USA
 18 January 2016 
H. pylori and gastric cancer across Europe
 18 January 2016 
Enteral nutrition in children with Crohn's
 15 January 2016 
Alcohol- and HCV-related hepatocellular carcinoma
 15 January 2016 
Recurrent colonic diverticulitis
 15 January 2016 
Colonic diverticula and colorectal cancer risk
 14 January 2016 
Risk stratification of incidentally discovered gallstones
 14 January 2016 
Treatment of refractory cholestatic pruritus
 14 January 2016 
Colonic diverticula and colorectal cancer risk 
 13 January 2016 
C-section delivery and IBD risk
 13 January 2016 
Primary biliary cholangitis treatment with incomplete UDCA response
 13 January 2016 
Colon cancer screening rates 
 12 January 2016 
Eosinophilic esophagitis endoscopic reference score
 12 January 2016 
Web-based tool for Crohn's disease
 12 January 2016 
IBD patients willingnes to accept medication risk
 11 January 2016 
HCV and increased cardiovascular mortality
 11 January 2016 
Urinary tract cancers in IBD
 11 January 2016 
Race and eosinophilic esophagitis

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2016 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us